ArticleACS nano2024
Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions.
Abstract read
In one paragraph
Article in ACS nano, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Nanomedicine-based cancer immunotherapy: translational barriers, mechanistic strategies, and future perspectives.Drug delivery · 2026Review
- Bio-based nanomaterials in drug delivery: An updated review.Pharmaceutical science advances · 2026Review
- Bufalin-Loaded Multifunctional Nanodrugs for Cancer Therapy: Mechanisms, Delivery Strategies, and Translational Perspectives.Biomolecules · 2026Review
- Metal nanoparticles as next-generation therapeutics against antimicrobial resistance: mechanisms, functionalization, and translational potential.Molecular biology reports · 2026Review
- Nanoparticulate and Hydrogel Vehicles for Stimuli-Responsive and Sustained Controlled Release of Active Pharmaceutical Ingredients.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Engineering Polymeric Nano-PROTAC for Targeted Protein Degradation and Cancer Therapy.Polymer science & technology (Washington, D.C.) · 2026Review
- Development of Sub-50 nm Core-Shell Silica Nanoparticles With Controlled In Vivo Behavior forAngewandte Chemie (International ed. in English) · 2026Article
- Protein-Based Nanomaterials for Cancer Therapy: A Comparative and Translational Perspective.Pharmaceutics · 2026Review
- Lipid Composition Determines Hybrid Nanoparticle Selectivity: Beyond Membrane Mimicry in Cancer Targeting.Nano letters · 2026Article
- Tumor organoids as a revolutionary platform for advancing cancer nanomedicine.Molecular cancer · 2026Review
- Precision nanomedicine for lung metastatic osteosarcoma: challenges, therapeutic strategies, and perspectives.Materials today. Bio · 2026Review
- The RNA delivery dilemma-lipid versus polymer nanoparticle platforms.Drug delivery and translational research · 2026Article
- Aptamer-Functionalized Nanocarriers for Bone and Joint Diseases: Engineering Design Rules and Translational Roadmap.Small science · 2026Article
- Artificial intelligence empowered biomaterials for cancer therapy: From rational design to clinical translation.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- Understanding and Exploiting Biological Mechanisms of Radiosensitization Using High Atomic Mass Nanomaterials.Nanomaterials (Basel, Switzerland) · 2026Review
- Atlas-Guided Nanocarrier Strategies Targeting Spatial NTRK2/MAPK Signaling in EGFR-TKI-Resistant Niches of Esophageal Squamous Cell Carcinoma.Pharmaceutics · 2026Review
- Intravital microscopy for nanomedicine: investigating nanoparticle-tissue interactions in the native state.RSC advances · 2026Review
- Key Tumor Responsive ZIF-8 Nanocarriers for Effective Anti-Cancer Therapeutics.International journal of nanomedicine · 2026Review
- DHA Targets RAB1B to Mediate the Driving Force Transmission of Copper Ion Vesicular Endocytosis Under Copper Overload for Promoting Cuproptosis and Ferroptosis in Hepatic Stellate Cells.International journal of biological sciences · 2026Article
- Piperine: From Green Extraction to Clinical Translation-A Review.Drug design, development and therapy · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
28 authors.
Thomas AnchordoquyDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, the University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Natalie ArtziBrigham and Woman's Hospital, Department of Medicine, Division of Engineering in Medicine, Harvard Medical School, Boston, Massachusetts 02215, United States.ORCID 0000-0002-2211-6069
Irina V BalyasnikovaDepartment of Neurological Surgery, Feinberg School of Medicine, Northwestern University; Northwestern Medicine Malnati Brain Tumor Institute of the Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611, United States.
Yechezkel BarenholzMembrane and Liposome Research Lab, IMRIC, Hebrew University Hadassah Medical School, Jerusalem 9112102, Israel.
Ninh M La-BeckDepartment of Immunotherapeutics and Biotechnology, Jerry H. Hodge School of Pharmacy, Texas Tech University Health Sciences Center, Abilene, Texas 79601, United States.ORCID 0000-0002-1956-3263
Jacob S BrennerDepartments of Medicine and Pharmacology, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Warren C W ChanInstitute of Biomedical Engineering, University of Toronto, Rosebrugh Building, 164 College Street, Toronto, Ontario M5S 3G9, Canada.ORCID 0000-0001-5435-4785
Paolo DecuzziLaboratory of Nanotechnology for Precision Medicine, Italian Institute of Technology, 16163 Genova, Italy.ORCID 0000-0001-6050-4188
Agata A ExnerDepartments of Radiology and Biomedical Engineering, Case Western Reserve University School of Medicine, Cleveland, Ohio 44106, United States.ORCID 0000-0003-3913-7066
Alberto GabizonThe Helmsley Cancer Center, Shaare Zedek Medical Center and The Hebrew University of Jerusalem-Faculty of Medicine, Jerusalem, 9103102, Israel.
Biana GodinDepartment of Nanomedicine, Houston Methodist Research Institute, Houston, Texas 77030, United States.
Samuel K LaiDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0003-4721-528X
Twan LammersDepartment of Nanomedicine and Theranostics, Institute for Experimental Molecular Imaging, Center for Biohybrid Medical Systems, University Hospital RWTH Aachen, 52074 Aachen, Germany.ORCID 0000-0002-1090-6805
Michael J MitchellDepartment of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.ORCID 0000-0002-3628-2244
S Moein MoghimiSchool of Pharmacy, Newcastle University, Newcastle upon Tyne NE1 7RU, U.K.ORCID 0000-0003-0836-926X
Vladimir R MuzykantovDepartment of Systems Pharmacology and Translational Therapeutics, The Perelman School of Medicine, The University of Pennsylvania, Philadelphia, Pennsylvania 19104, United States.
Dan PeerLaboratory of Precision Nanomedicine, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University, Tel Aviv, 69978, Israel.ORCID 0000-0001-8238-0673
Juliane NguyenDivision of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina 27599, United States.ORCID 0000-0002-8578-7396
Rachela PopovtzerFaculty of Engineering and the Institute of Nanotechnology & Advanced Materials, Bar-Ilan University, 5290002 Ramat Gan, Israel.
Madison RiccoDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, the University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Natalie J SerkovaDepartment of Radiology, University of Colorado Cancer Center, Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Ravi SinghDepartment of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, North Carolina 27101, United States.ORCID 0000-0003-0750-1804
Avi SchroederDepartment of Chemical Engineering, Technion, Israel Institute of Technology, Haifa 32000, Israel.ORCID 0000-0003-2571-5937
Anna A SchwendemanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Michigan 48108; Biointerfaces Institute, University of Michigan, Ann Arbor, Michigan 48108, United States.ORCID 0000-0002-8023-8080
Joelle P StraehlaDana-Farber/Boston Children's Cancer and Blood Disorders Center, Boston, Massachusetts 02115 United States.ORCID 0000-0002-9446-1718
Tambet TeesaluLaboratory of Precision and Nanomedicine, Institute of Biomedicine and Translational Medicine, University of Tartu, 50411 Tartu, Estonia.
Scott TildenDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, the University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.
Dmitri SimbergDepartment of Pharmaceutical Sciences, The Skaggs School of Pharmacy and Pharmaceutical Sciences, the University of Colorado Anschutz Medical Campus, Aurora, Colorado 80045, United States.ORCID 0000-0002-5288-6275
Funding
Immune Tolerance Network UM1 2023 SupplementUM1AI109565 · NIAID · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI Mark S Anderson, Jane Hoyt Buckner · 2014 to 2026
$451.6MUniversity of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0MColorado Clinical and Translational Sciences Institute (CCTSI)UM1TR004399 · NCATS · UNIVERSITY OF COLORADO DENVER · PI JANINE A HIGGINS, RONALD J. SOKOL · 2023 to 2026
$30.7MFluorescent Indocarbocyanine PEGylated Lipid Nanoparticles for Understanding and Overcoming Barriers to Drug Delivery in Invasive GlioblastomaR01CA257958 · NCI · UNIVERSITY OF COLORADO DENVER · PI Irina V Balyasnikova, Dmitri Simberg · 2022 to 2026
$2.7MOvercoming anti-PEG immunity to restore prolonged circulation and efficacy of PEGylated therapeuticsR01HL141934 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI LAI, SAMUEL, ZAMBONI, WILLIAM C · 2018 to 2021
$2.7MMaximizing Therapeutic Accumulation and Retention for Enhanced Cardiac RepairR01HL174038 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Juliane Nguyen · 2024 to 2026
$2.1MEngineering a cross-linked cellular network for cardiac repairR01HL161456 · NHLBI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI NGUYEN, JULIANE · 2022 to 2025
$1.9MDevelopment of a novel therapeutic agent that exploits specific vulnerabilities in claudin low breast cancerR01CA207222 · NCI · WAKE FOREST UNIVERSITY HEALTH SCIENCES · PI SINGH, RAVI N · 2017 to 2021
$1.7MIntranasal Delivery of Telomerase Reverse Transcriptase mRNA for Therapy ofTraumatic Brain InjuryR21NS127265 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI GODIN, BIANA, VILLAPOL, SONIA · 2022 to 2022
$444kMechanisms and Barriers in Nanomedicine-2023R13EB034603 · NIBIB · UNIVERSITY OF COLORADO DENVER · PI ANCHORDOQUY, THOMAS, SIMBERG, DMITRI · 2023 to 2023
$15kEuropean Research Council 101055029NCATS NIH HHS UM1 TR004399NCI NIH HHS P30 CA046934NCI NIH HHS R01 CA207222NCI NIH HHS R01 CA257958NHLBI NIH HHS R01 HL141934NHLBI NIH HHS R01 HL161456NHLBI NIH HHS R01 HL174038NIAID NIH HHS UM1 AI109565NIBIB NIH HHS R13 EB034603NINDS NIH HHS R21 NS127265
Abstract
In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop "Mechanisms and Barriers in Nanomedicine" in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.
Indexed as
NanomedicineDrug CarriersHumansLiposomesNanoparticlesUnited StatesDrug CarriersLiposomesbarrierscomplementdeliveryformulationinflammationmRNAnanomedicinetranslationtumor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.